Abstract: Disclosed is a poultice capable of rapidly curing an affected part of a patient's body and of enhancing a curative value by increasing an infiltration efficiency of medicine into a hypodermic tissue of the affected part with the aid of a low-frequency electro therapy. Both surfaces of compress sheets of the poultice are coated with predetermined skin-adhesive medicines adapted to cure an affected part of a patient's body. A thin film is attached to lower surfaces of the compress sheets. The thin film can be detached from the lower surfaces of the compress sheets during use of the poultice. An attaching sheet for attaching the poultice to the affected part of the patient's body is located on upper surfaces of the compress sheets. A pair of conductive layers are coated on a lower surface of the attaching sheet, which is opposite to the upper surfaces of the compress sheets. A low-frequency oscillator for applying a low-frequency energy into the compress sheets is installed between the conductive layers.

Abstract: A process for preparing molding materials having anticoagulant properties is described. Hydrophobic monomers are subjected to free-radical copolymerization with hydrophilic monomers having biospecifically active functions to produce the molding material. The molding material may then be shaped into articles which also have anticoagulant properties. These articles are extremely useful in, for example, medical applications in contact with a patient's biological fluid.

Abstract: The present invention relates to pesticide compositions in which at least one of the components of the composition is a polymeric material which reduces the rate of crystallization of the pesticide active ingredient in the composition. This invention also provides a method for reducing the rate of crystallization of pesticide active ingredients and a method for controlling pests comprising applying to the pest the polymer-containing composition.

Abstract: The present invention relates to an aqueous composition for reducing malodor impression. The composition comprises from about 0.01% to about 1%, by weight of the composition, of perfume. Optionally, but preferably, the composition comprises from about 0.1% to about 5%, by weight of the composition of, water-soluble cyclodextrin, from about 0.1% to about 10%, by weight of the composition, of water-soluble metallic salt, from about 0% to about 3%, by weight of the composition, of solubilizing aid. The composition is essentially free of any material that would soil or stain fabric and contains less than about 5%, by weight of the composition of low molecular weight monohydric alcohols.

Abstract: Water-soluble borate-polyol complexes are useful as buffers and/or antimicrobials in aqueous ophthalmic compositions, including those containing polyvinyl alcohol. These compositions have greater antimicrobial activity than comparable compositions containing typical borate buffers and unexpectedly increase the antimicrobial efficacy of other antimicrobial agents when used in combination. In addition, use of the borate-polyol complexes avoids the incompatibility problem typically associated with the combination of borate buffer and polyvinyl alcohol; therefore, the compositions disclosed herein may also contain polyvinyl alcohol.

Abstract: Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37.degree. C. of from about 12.5% to about 42.5% (by wt) opioid released after 1 hour, from about 25% to about 65% (by wt) opioid released after 2 hours, from about 45% to about 85% (by wt) opioid released after 4 hours, and greater than about 60% (by wt) opioid released after 8 hours, the in-vitro release rate being substantially independent of pH and chosen such that the peak plasma level of said opioid analgesic obtained in-vivo occurs from about 2 to about 8 hours after administration of the dosage form.

Abstract: The present invention relates to a novel pharmaceutical form, in the form of spheroids, containing tiagabine as active principle. The invention also covers the process for the preparation of such spheroids and multiparticulate pharmaceutical preparations, such as tablets, containing these spheroids. These pharmaceutical preparations are intended for the delivery of the spheroids they contain, and are characterized by the absence of an adverse effect on the release profile of the tiagabine contained in the spheroids following a possible compression step.

Abstract: This invention pertains to the use of a combination of angiotensin inhibitors and nitric oxide stimulators to slow and reverse the process of fibrosis in the body. This combination of medicaments is particularly useful in the treatment of a variety of cardiovascular fibrotic pathologies, such as that associated with left ventricular hypertrophy secondary to hypertension, myocardial infarction, and myocarditis.

Abstract: Preparation for reducing the bond strength of adhesive tapes, consisting of at least one penetrant and at least one bond strength-reducing active substance which is skin-compatible and may make an active contribution to skincare, where the bond strength-reducing active substance contains at least one hydrocarbon chain of the form (C.sub.n H.sub.m) where n is the number of carbon atoms in the chain and has a value of greater than 6, and where the adhesive-reducing [sic] active substance has a primary irritation index of less than 3, with particular preference 0.

Abstract: A pharmaceutical composition has an acid salt of a sympathomimetic amine; and a denaturant of (i) at least one gum or viscosity modifier, and (ii) at least one surfactant, wherein the gum or viscosity modifier and the surfactant are present in amounts sufficient to have a denaturing effect on the sympathomimetic amine without significantly compromising the release of the sympathomimetic amine from the composition.

Abstract: An aqueous liquid composition comprising:a. a cleansing effective amount of a surfactant or mixture thereof;b. an antioxidant effective amount of a material selected from the group consisting of vitamin E, vitamin C, vitamin A, a precursor of any of these said vitamins which is converted to the respective vitamin E, C and A when said precursor is contacted with skin, and mixtures thereof; andc.

Abstract: The use of compound 1 and/or 2 of the formulae ##STR1## and of physiologically tolerable salts of compound 2 for the treatment of rejection reactions of the organ recipient to the transplanted organ is described.

Abstract: Multilayer interference pigment consisting of a central, absorbing layer and alternating layers of a material of low refractive index and of a metal or of a material of high refractive index either side of the central layer, the material of low refractive index preferably being acrylate and the metal being aluminium or chromium. The absorbing layer consists of a coating system which comprises carbon black or color-imparting absorption pigments.

Abstract: A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and relative humidity elevated to a suitable level above ambient conditions until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.

Abstract: A method for treating urinary incontinence, such as incontinence resulting from bladder detrusor muscle instability, using enantiomerically enriched (S)-procyclidine. The method comprises administering a therapeutically effective amount of enantiomerically enriched (S)-procyclidine, or a pharmaceutically acceptable salt thereof, substantially free of the (R)-procyclidine enantiomer. Pharmaceutical compositions for the treatment of urinary incontinence comprising enantiomerically enriched (S)-procyclidine, or a pharmaceutically acceptable salt thereof, and an acceptable carrier are also disclosed.

Abstract: An animal feed composition for reducing colonization of animal intestines by Salmonella and other bacterial pathogens, includes a polysaccharide containing cis-hydroxy sugar units or a derivative thereof, or the monosaccharide ribose or rhamnose, or a derivative thereof, and an animal feed. The polysaccharide cis-hydroxy sugar units may be one or more of mannose, a mannose derivative, galactose, a galactose derivative, galactomannans, galactosamine, fucose and arabinose. The polysaccharides may be incorporated into an animal feed in the form of a food gum or other biolpolymer.

Abstract: A stable crystalline powdery saccharide having a crystallinity of 40% or more, less hygroscopicity, satisfactory fluidity, and beneficial handleability, which is obtainable from an aqueous solution, containing trehalose and a different saccharide(s) crystallizable in the presence of trehalose, by crystallizing the trehalose along with the different saccharide(s).

Abstract: A stable aqueous liquid comprising surfactant, dispersed cationic polymer particle and small particle benefit agent. The dispersed polymer interacts with the benefit agent, without need of additional structurant to stabilize particles in solution. Further, upon dilution, enhanced cationic deposition is achieved.

Abstract: Purpose: the purpose of the present invention is to offer resin compositions which have antimicrobial/fungistatic properties which show outstanding dispersion and outstandingly durable performance. Constitution: thermoplastic resin compositions characterized in that an antimicrobial/fungistatic agent, and particularly an inorganic antimicrobial/fungistatic agent, is compounded with a copolymer containing a polyether chain as a constituent unit, such as a polyether/polyamide copolymer, a polyether/polyester copolymer or a polyether urethane, for example, at 0.05-20 wt. %, and thermoplastic resin compositions which comprise a thermoplastic resin, an antimicrobial/fungistatic agent and a copolymer having a polyether chain as a constituent unit.

Abstract: Topical gelled compositions comprising an optional drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.